| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/09/2013 | CN101019905B Medicine composition containing tribulus fruit furostanol saponin and application thereof |
| 01/08/2013 | US8350060 2-amino-bicyclo[3.1.0] hexane-2, 6-dicarboxylic ester derivative |
| 01/08/2013 | US8350016 Oligonucleotide compositions and their use to induce apoptosis |
| 01/08/2013 | US8349896 Aspirin-triggered lipid mediators |
| 01/08/2013 | US8349888 Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury |
| 01/08/2013 | US8349862 Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia |
| 01/08/2013 | US8349843 Carboxylic acid derivatives, their preparation and use |
| 01/08/2013 | US8349831 Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion |
| 01/08/2013 | US8349817 Analogues of cilostazol |
| 01/08/2013 | US8349798 Caveolin peptides and their use as therapeutics |
| 01/08/2013 | US8349374 Inhibition of angiogenesis and destruction of angiogenic vessels with extracts of noni juice (Morinda citrifolia) |
| 01/08/2013 | CA2642539C Agent for preventing arteriosclerosis, agent for suppressing vascular intimal thickening and agent for improving vascular endothelial function |
| 01/08/2013 | CA2609595C Preventive and/or therapeutic agents for diabetic vascular disorders and respiratory disorders |
| 01/08/2013 | CA2590511C Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor |
| 01/08/2013 | CA2507710C Tricyclic pyrazole derivatives and their use as cb1 or cb2 modulators |
| 01/08/2013 | CA2500530C Therapeutic uses of .beta.-casein a2 and dietary supplement containing .beta.-casein a2 |
| 01/08/2013 | CA2490121C Modified phospholipids |
| 01/08/2013 | CA2485081C Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| 01/08/2013 | CA2478065C Macrocyclic compounds useful as pharmaceuticals |
| 01/08/2013 | CA2428782C Medicine based on anti-hyperglycaemic microcapsules with prolonged release and its method of preparation |
| 01/03/2013 | WO2013003641A2 Serpin fusion polypeptides and methods of use thereof |
| 01/03/2013 | WO2013003445A1 Tetra-pyridine compounds and composition for protecting cells, tissues and organs against ischemia-reperfusion injury |
| 01/03/2013 | WO2013002382A1 Nicorandil-containing pharmaceutical composition |
| 01/03/2013 | WO2013002313A1 Weight control drug |
| 01/03/2013 | WO2013002248A1 Phosphoric acid ester derivative |
| 01/03/2013 | WO2013001890A1 Soyasapogenol composition |
| 01/03/2013 | WO2013001819A1 SOLUBLE INTEGRIN α4 MUTANT |
| 01/03/2013 | WO2013001310A1 Macrocyclic compounds and their use as cdk8 inhibitors |
| 01/03/2013 | WO2013001130A1 Lrp1 as key receptor for the transfer of sterified cholesterol from very-low-density lipoproteins (vldl) to ischaemic cardiac muscle |
| 01/03/2013 | WO2013000895A1 Dha and epa in the reduction of oxidative stress |
| 01/03/2013 | WO2013000267A1 Azole heterocyclic compound, preparation method, pharmaceutical composition and use |
| 01/03/2013 | WO2013000108A1 Azole heterocylic compounds, preparation methods, pharmaceutical compositions and uses thereof |
| 01/03/2013 | WO2012148148A3 Novel zinc azide complex and a process for preparing tetrazole derivatives using the same |
| 01/03/2013 | WO2012140666A3 Herbal extracts and compositions prepared therefrom |
| 01/03/2013 | WO2012138880A9 Methods of treating inflammatory diseases by targeting the chemoattractant cytokine receptor 2 (ccr2) or chemokine (c-c motif) ligand 2 (ccl2) |
| 01/03/2013 | WO2012128502A9 Composition for promoting vasculogenesis comprising pauf |
| 01/03/2013 | WO2012123561A3 Agent for prophylaxis and treatment of age-associated diseases and disorders and for prolonging life |
| 01/03/2013 | US20130006351 Polymer coatings containing drug powder of controlled morphology |
| 01/03/2013 | US20130006350 Drug-delivery endovascular stent and method for treating restenosis |
| 01/03/2013 | US20130005824 Treatment of ischemic tissue |
| 01/03/2013 | US20130005820 Agomelatine hydrochloride hydrate and preparation thereof |
| 01/03/2013 | US20130005802 Treatment of wnt/frizzled-related diseases |
| 01/03/2013 | US20130005796 Method for proliferating cardiomyocytes using micro-rna |
| 01/03/2013 | US20130005784 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| 01/03/2013 | US20130005782 Method for integrin ligand discovery |
| 01/03/2013 | US20130005778 Urethanes, ureas, amidines and related inhibitors of factor xa |
| 01/03/2013 | US20130005770 Organic compounds |
| 01/03/2013 | US20130005762 Combination of droloxifene and clopidogrel |
| 01/03/2013 | US20130005752 Metalloenzyme inhibitor compounds |
| 01/03/2013 | US20130005742 Substituted Diphenylpyrazine Derivatives |
| 01/03/2013 | US20130005741 Substituted pyrimidine as a prostaglandin d2 receptor antagonist |
| 01/03/2013 | US20130005739 Pharmaceutical preparations comprising a cos releasing compound |
| 01/03/2013 | US20130005734 Therapeutic compositions |
| 01/03/2013 | US20130005731 Crystalline forms of neurotrophin mimetic compounds and their salts |
| 01/03/2013 | US20130005730 Novel 1,3-oxazolidine compounds and their use as renin inhibitors |
| 01/03/2013 | US20130005729 Metalloenzyme inhibitor compounds |
| 01/03/2013 | US20130005728 Substituted pyrimidines as prostaglandin d2 receptor antagonists |
| 01/03/2013 | US20130005727 Quinazoline derivatives |
| 01/03/2013 | US20130005724 Pyridino-pyridinone derivatives, preparation and therapeutic use thereof |
| 01/03/2013 | US20130005721 Indolizine inhibitors of 5-lipoxygenase |
| 01/03/2013 | US20130005707 Aminotriazolopyridines, compositions thereof, and methods of treatment therewith |
| 01/03/2013 | US20130005706 Fused heterocyclic compounds as ion channel modulators |
| 01/03/2013 | US20130005704 Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors |
| 01/03/2013 | US20130005701 Substituted oxazolidinones and their use in the field of blood coagulation |
| 01/03/2013 | US20130005694 Liquid compositions comprising vitamin d and uses thereof |
| 01/03/2013 | US20130005692 Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome |
| 01/03/2013 | US20130005675 Quinolone compound and pharmaceutical composition |
| 01/03/2013 | US20130005670 COMBINATION COMPOSITION, COMPRISING AS ACTIVE INGREDIENTS L-CARNITlNE OR PROPIONYL L-CARNITlNE, FOR THE PREVENTION OR TREATMENT OF CHRONIC VENOUS INSUFFICIENCY |
| 01/03/2013 | US20130005658 Micro-rna regulation in ischemia and ischemia-reperfusion injury |
| 01/03/2013 | US20130005646 Polypeptides |
| 01/03/2013 | US20130005645 Apoe peptide dimers and uses thereof |
| 01/03/2013 | US20130005644 Cyclic agonists and antagonists of c5a receptors and g protein-coupled receptors |
| 01/03/2013 | US20130004596 Pharmaceutical composition for treating diabetes containing quamoclit angulata extract |
| 01/03/2013 | US20130004573 Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride |
| 01/03/2013 | US20130004572 Stable pharmaceutical composition and methods of using same |
| 01/03/2013 | US20130004567 Methods of treating hypertriglyceridemia |
| 01/03/2013 | US20130004566 Methods of treating hypertriglyceridemia |
| 01/03/2013 | US20130004565 Proteolytic enzyme formulations |
| 01/03/2013 | US20130004551 Biotinylated hexadecasaccharides, preparation and use thereof |
| 01/03/2013 | US20130004548 Medical devices having pharmacological active agent releasing material |
| 01/03/2013 | US20130004515 Methods for treating reperfusion injuries |
| 01/03/2013 | US20130004514 Therapeutic antibodies |
| 01/03/2013 | US20130004507 METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES |
| 01/03/2013 | US20130004506 Method for treating pathologies associated with hypoxia using mif inhibitors |
| 01/03/2013 | US20130004498 Dosing for treatment with anti-egfl7 antibodies |
| 01/03/2013 | US20130004491 Antibodies Against Phosphorylcholine In Combination Therapy with Biologic Agents |
| 01/03/2013 | US20130004488 Anti-cancer agent delivery vehicles capable of improved loading |
| 01/03/2013 | US20130004487 Scd40l and placental growth factor (pigf) as biochemical marker combinations in cardiovascular diseases |
| 01/03/2013 | US20130004477 Methods for Treating Inflammation and Oxidative Stress Related Diseases |
| 01/03/2013 | US20130004469 Engineered lumenized vascular networks and support matrix |
| 01/03/2013 | US20130004465 Adherent cells from placenta and use of same in disease treatment |
| 01/03/2013 | US20130004464 Multipotent adult stem cell population |
| 01/03/2013 | US20130004460 Silylated biomolecules |
| 01/03/2013 | US20130004455 Poly(organophosphazene) composition for biomaterials |
| 01/03/2013 | US20130004434 Gastroretentive, Extended Release Composition Of Therapeutic Agent |
| 01/03/2013 | US20130004428 Diazabicyclononyl oxadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| 01/03/2013 | US20130004426 Adenosine derivative formulations for medical imaging |
| 01/03/2013 | US20130004416 Dual Variable Domain Immunoglobulin and Uses Thereof |
| 01/03/2013 | US20130004415 Joint-Homing Peptides and Uses Thereof |
| 01/03/2013 | CA2877891A1 Process for preparing heparinoids and intermediates useful in the synthesis thereof |